FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210094726> ?p ?o ?g. }

• W3210094726 endingPage "189" @default.
• W3210094726 startingPage "178" @default.
• W3210094726 abstract "Introduction: This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adolescents and adults with type 1 diabetes (T1D). Materials and Methods: This multicenter single-arm study involved an intent-to-treat population of 157 individuals (39 adolescents aged 14-21 years and 118 adults aged ≥22-75 years) with T1D. Study participants used the MiniMed™ AHCL system during a baseline run-in period in which sensor-augmented pump +/- predictive low glucose management or Auto Basal was enabled for ∼14 days. Thereafter, Auto Basal and Auto Correction were enabled for a study phase (∼90 days), with glucose target set to 100 or 120 mg/dL for ∼45 days, followed by the other target for ∼45 days. Study endpoints included safety events and change in mean A1C, time in range (TIR, 70-180 mg/dL) and time below range (TBR, <70 mg/dL). Run-in and study phase values were compared using Wilcoxon signed-rank test or paired t-test. Results: Overall group time spent in closed loop averaged 94.9% ± 5.4% and involved only 1.2 ± 0.8 exits per week. Compared with run-in, AHCL reduced A1C from 7.5% ± 0.8% to 7.0% ± 0.5% (<0.001, Wilcoxon signed-rank test, n = 155), TIR increased from 68.8% ± 10.5% to 74.5% ± 6.9% (<0.001, Wilcoxon signed-rank test), and TBR reduced from 3.3% ± 2.9% to 2.3% ± 1.7% (<0.001, Wilcoxon signed-rank test). Similar benefits to glycemia were observed for each age group and were more pronounced for the nighttime (12 AM-6 AM). The 100 mg/dL target increased TIR to 75.4% (n = 155), which was further optimized at a lower active insulin time (AIT) setting (i.e., 2 h), without increasing TBR. There were no severe hypoglycemic or diabetic ketoacidosis events during the study phase. Conclusions: These findings show that the MiniMed AHCL system is safe and allows for achievement of recommended glycemic targets in adolescents and adults with T1D. Adjustments in target and AIT settings may further optimize glycemia and improve user experience. Clinical Trial Registration number: NCT03959423." @default.
• W3210094726 created "2021-11-08" @default.
• W3210094726 creator A5002453229 @default.
• W3210094726 creator A5003428235 @default.
• W3210094726 creator A5003450540 @default.
• W3210094726 creator A5004911939 @default.
• W3210094726 creator A5005036709 @default.
• W3210094726 creator A5007119846 @default.
• W3210094726 creator A5018561083 @default.
• W3210094726 creator A5018679082 @default.
• W3210094726 creator A5022173666 @default.
• W3210094726 creator A5027624056 @default.
• W3210094726 creator A5034545668 @default.
• W3210094726 creator A5045954041 @default.
• W3210094726 creator A5046354867 @default.
• W3210094726 creator A5048941594 @default.
• W3210094726 creator A5051262919 @default.
• W3210094726 creator A5054183066 @default.
• W3210094726 creator A5057232862 @default.
• W3210094726 creator A5065501820 @default.
• W3210094726 creator A5069888436 @default.
• W3210094726 creator A5072334144 @default.
• W3210094726 creator A5073960083 @default.
• W3210094726 creator A5076633688 @default.
• W3210094726 creator A5076715530 @default.
• W3210094726 creator A5083954285 @default.
• W3210094726 creator A5085399860 @default.
• W3210094726 date "2022-03-01" @default.
• W3210094726 modified "2023-10-14" @default.
• W3210094726 title "Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes" @default.
• W3210094726 cites W1607126000 @default.
• W3210094726 cites W2075361652 @default.
• W3210094726 cites W2098570086 @default.
• W3210094726 cites W2232527743 @default.
• W3210094726 cites W2407185352 @default.
• W3210094726 cites W2520448718 @default.
• W3210094726 cites W2553292368 @default.
• W3210094726 cites W2564509157 @default.
• W3210094726 cites W2566952971 @default.
• W3210094726 cites W2587843318 @default.
• W3210094726 cites W2769264260 @default.
• W3210094726 cites W2770616601 @default.
• W3210094726 cites W2889348059 @default.
• W3210094726 cites W2891930016 @default.
• W3210094726 cites W2891956083 @default.
• W3210094726 cites W2905988917 @default.
• W3210094726 cites W2906596531 @default.
• W3210094726 cites W2909102766 @default.
• W3210094726 cites W2909166675 @default.
• W3210094726 cites W2910274134 @default.
• W3210094726 cites W2921469451 @default.
• W3210094726 cites W2925318091 @default.
• W3210094726 cites W2947202425 @default.
• W3210094726 cites W2948261890 @default.
• W3210094726 cites W2956035030 @default.
• W3210094726 cites W2974891484 @default.
• W3210094726 cites W2976192468 @default.
• W3210094726 cites W2980084193 @default.
• W3210094726 cites W2981310284 @default.
• W3210094726 cites W2986909781 @default.
• W3210094726 cites W2993032844 @default.
• W3210094726 cites W2995085977 @default.
• W3210094726 cites W2995689063 @default.
• W3210094726 cites W2998687282 @default.
• W3210094726 cites W3080495660 @default.
• W3210094726 cites W3098183377 @default.
• W3210094726 cites W3118986275 @default.
• W3210094726 cites W3124172438 @default.
• W3210094726 cites W3129111678 @default.
• W3210094726 cites W3152062881 @default.
• W3210094726 cites W3159211340 @default.
• W3210094726 cites W3166779635 @default.
• W3210094726 cites W3170744568 @default.
• W3210094726 doi "https://doi.org/10.1089/dia.2021.0319" @default.
• W3210094726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34694909" @default.
• W3210094726 hasPublicationYear "2022" @default.
• W3210094726 type Work @default.
• W3210094726 sameAs 3210094726 @default.
• W3210094726 citedByCount "72" @default.
• W3210094726 countsByYear W32100947262022 @default.
• W3210094726 countsByYear W32100947262023 @default.
• W3210094726 crossrefType "journal-article" @default.
• W3210094726 hasAuthorship W3210094726A5002453229 @default.
• W3210094726 hasAuthorship W3210094726A5003428235 @default.
• W3210094726 hasAuthorship W3210094726A5003450540 @default.
• W3210094726 hasAuthorship W3210094726A5004911939 @default.
• W3210094726 hasAuthorship W3210094726A5005036709 @default.
• W3210094726 hasAuthorship W3210094726A5007119846 @default.
• W3210094726 hasAuthorship W3210094726A5018561083 @default.
• W3210094726 hasAuthorship W3210094726A5018679082 @default.
• W3210094726 hasAuthorship W3210094726A5022173666 @default.
• W3210094726 hasAuthorship W3210094726A5027624056 @default.
• W3210094726 hasAuthorship W3210094726A5034545668 @default.
• W3210094726 hasAuthorship W3210094726A5045954041 @default.
• W3210094726 hasAuthorship W3210094726A5046354867 @default.
• W3210094726 hasAuthorship W3210094726A5048941594 @default.
• W3210094726 hasAuthorship W3210094726A5051262919 @default.
• W3210094726 hasAuthorship W3210094726A5054183066 @default.

• next